AlphAIalphai — Financial news for AI agents
SEC EDGARJUN 21 min read$GLUE

Warmuth Markus sold $9K of GLUE

Warmuth Markus (President & CEO) sold 468 shares of Monte Rosa Therapeutics, Inc. (GLUE) at $19.73 on 2026-06-01 under a Rule 10b5-1 trading plan.

Original reporting
SEC EDGAR · Warmuth Markus
Published Jun 2, 2026, 8:05 PM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Jun 2, 2026, 8:11 PM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About alphai AI DeskScoring methodologyReport an issue
alphai market briefInsider activity
Primary signal
$GLUE
Neutral
medium confidence
Mentioned
$GLUE
Relevance
6/10
alphai data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$GLUENeutralLow
01

Why it matters

This disclosure updates the record of insider activity but does not introduce new operational, clinical, or financial information.

02

Market read

Traders may note insider activity, but the pre-arranged nature and small dollar value suggest limited tradable impact.

03

What to watch

The sale size is relatively small ($9.2K) versus holdings; without additional context (e.g., multiple concurrent sales), the signal is weak.

Relevance 6/10Novelty 2/10Timing: Filed after-hours/late day (2026-06-02), reflecting a 2026-06-01 sale.

Background

SEC Form 4 insider transaction: CEO Warmuth Markus sold shares on 2026-06-01; the plan is pre-arranged under Rule 10b5-1.

Company-level read

Ticker impact

$GLUENeutralMedium confidence
Context

Monte Rosa Therapeutics CEO sold 468 shares in an open-market transaction disclosed via SEC Form 4 under a 10b5-1 plan.

Expected impact

Likely minimal near-term price impact; any reaction is more sentiment/noise than fundamentals.

Evidence & confidence

The filing provides a specific sale price/value and confirms a pre-arranged 10b5-1 plan, which typically reduces interpretive weight.

Market effects

Sector

No direct sector read-through; this is company-specific insider transaction disclosure.

Regional

None.

Global

None.

Counterpoint

What could challenge this read

Even with a 10b5-1 plan, repeated insider selling can still coincide with management’s view of near-term risk, potentially affecting sentiment.

Key entities

  • issuer
    Monte Rosa Therapeutics, Inc.

    Subject of the Form 4 insider sale by its President & CEO.

  • insider
    Warmuth Markus

    President & CEO who sold 468 shares at $19.7262 via open-market sale under a 10b5-1 plan.

Read at source← All news

Related articles

AUG 6
$GLUEMed

Monte Rosa Therapeutics reports Q2 2026 net loss $43.4M, cash position $626.0M supporting operations into 2029

Monte Rosa Therapeutics reported a Q2 2026 net loss of $43.4M, with collaboration revenue of $9.0M. Cash, cash equivalents, restricted cash, and marketable securities totaled $626.0M as of June 30, 2026, supporting operations into 2029. R&D and G&A rose year over year. The company advanced MRT-8102 and other programs, including Novartis-activated MRT-6160 Phase 2.

tradingview.com1 min
AUG 6
$GLUEMed

Monte Rosa Therapeutics, Inc. (GLUE): Results of Operations and Financial Condition

Monte Rosa Therapeutics, Inc. (GLUE) filed an SEC Form 8-K — Results of Operations and Financial Condition. EX-99.1 2 glue-ex99_1.htm EX-99.1 EX-99.1 Exhibit 99.1 Monte Rosa Therapeutics Announces Second Quarter 2026 Financial Results and Business Updates Completed enrollment and dosing for GFORCE-1 study of MRT-8102 in subjects with elevated cardiovascular disease (CVD) risk; readout

SEC EDGAR 8-K6 min
JUL 31
$GLUEMed

Why is Monte Rosa Therapeutics stock plunging today?

Amazon shares rally as cloud growth surges and spending outlook climbs Investing.com -- Monte Rosa Therapeutics shares plummeted nearly 29.9% in pre-open trading today, trading at $15.90, after Novo Nordisk disclosed that its Phase 3 ZEUS cardiovascular outcomes trial for ziltivekimab — an IL-6 pathway inhibitor — failed to demonstrate a statistically meaningful reduction in major adverse cardiovascular events versus placebo in patients with atherosclerotic cardiovascular disease, chronic...

investing.com4 min
JUN 5
$GLUEMedAI 9/10

Monte Rosa Therapeutics (GLUE): Best Growth Stocks Under $20 to Buy

Monte Rosa Therapeutics (GLUE) reported May 7 progress in its clinical pipeline, with three programs moving toward Phase 2. MRT-8102 (NEK7) showed CRP reductions in early trials and plans multiple Phase 2 starts in H2 2026. MRT-6160 (VAV1) with Novartis and MRT-2359 (GSPT1) in mCRPC also advance, with a Phase 2 combo with apalutamide planned for Q3 2026. The company reported $671M cash, expected to fund operations into 2029.

finance.yahoo.com4 min
MAY 29
$GLUEMedAI 9/10

Molecule glue drugs shake up cancer care, draw big money

Revolution Medicines (RevMed) said its daraxonrasib doubled survival in aggressive pancreatic cancer, from 6.7 to 13.2 months, with final-stage results due at a Chicago medical conference. The outcome has spurred dealmaking and development of “molecular glue” drugs targeting “undruggable” proteins. RevMed’s market cap neared $33B; it plans FDA filing and an ultrafast review, with projected $7B annual sales by 2032.

economictimes.indiatimes.com6 min